# A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct06568692/  
OnCo record `nct06568692` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Capecitabine in triple-negative breast cancer, run by Processa Pharmaceuticals, now recruiting.

## Summary

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06568692 by Processa Pharmaceuticals, with 90 participants planned, started 2024-10-02 and due to reach its primary completion in 2026-09. Interventions recorded: PCS6422 and capecitabine and Capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06568692
- Phase: 2
- Setting: A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Sponsor: Processa Pharmaceuticals
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06568692: https://clinicaltrials.gov/study/NCT06568692

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct06568692.json